Novartis Showcases Latest Hematology Research at the 65th American Society of Hematology Annual Meeting

Nov 12, 2023 18:02 CST Updated 18:02

Novartis

Drug Development and Manufacturing

The 65th American Society of Hematology (ASH) Annual Meeting will be held both in-person and online from December 9 to 12, 2023. Clinical and real-world research findings on Novartis' therapeutic drugs in the field of hematological disorders will be presented at this conference. Let’s take a sneak peek at the highlights.

Related Highlights Let's Take a Sneak Peek:

Novartis Hematology-Related Research Achievements

CML, MPN, GvHD, ITP, SAA, PNH and other fields

Total 82 Reports

Exploration of Nilotinib in the Treatment of CML for Achieving TFROral Report 446

Final Analysis of the ASCEMBL Study Results, Patient Baseline Mutations, and Impact AnalysisOral Report 449

ASCEND: A 48-Week Analysis of the Efficacy and Safety of STAMP Inhibitors as First-Line Treatment for CML-CPOral Report 865

X2101: Final Results Analysis of STAMP Inhibitor Monotherapy and Combination TherapyOral Report 450, 868

Real-world Experience with STAMP InhibitorsPoster 4541, 1809, 1803

AIM4CML: Exploration of Different Doses and Frequencies of STAMP Inhibitor MonotherapyPoster 3172

Development and Validation of Deep Learning Models —— Human-Machine Collaboration, Assisting in MPN Subtype DiagnosisOral Report 123

From raising scientific questions to exploring clinical translation

Model validation initiated by Jiangsu Provincial People's Hospital with multi-center participation

JUMP Study: Analysis of Ruxolitinib Treatment in 2233 Patients with MFPoster 5174

REVEAL Study: Assessment of Risk Factors for Disease Progression in PV PatientsOral Report 385

Germany GSG-MPN PV StudyOral Report 619

RESPONSE/RESPONSE2 Meta-AnalysisPoster 4553

REACH Series Study Data Update: REACH3 – Final Analysis Results at 3 YearsOral Report 654

Other Research Explorations:Multicenter Phase II StudyOral Report 653, 775

Eltrombopag for the Treatment of ITP:

Update on Phase III Study of Eltrombopag in Newly Diagnosed Pediatric ITP PatientsPoster 1223

IWISh 2.0 Results: Unmet Needs in ITP TreatmentPoster 1212

APPLY Study 48-Week Final AnalysisOral Report 571

APPLY & APPOINT Study on Patient-Reported Outcomes AnalysisOral Report 487

Multiple Research Posters and Abstracts

APPLY & APPOINT Hematological Response4084

APPLY & APPOINT BTH Analysis1338

Single-Dose PK and PD Study2723 4096

BAFF-R Monoclonal Antibody

Unique Dual Mechanism of Action:

NK Cell-Mediated ADCC

Blocking B-cell differentiation, proliferation, and survival signals

Shows great potential in ITP, wAIHA, CLL, and NHL.

Please stay tuned for the series of academic activities by Novartis Medical Department after the ASH meeting.
Data Interpretation in Hematological Diseases Field: December 12th - 20th
ASH Post-Conference Series 2024 January - March

Approval Code IPT0012579-37378, valid until 2024-11-10, expired documents are deemed invalid.

Typesetting: Moly

Execution:Moly

This platform aims to convey more medical information to healthcare professionals. The content published on this platform cannot replace professional medical guidance in any way and should not be regarded as diagnostic or treatment advice. If such information is used for purposes other than understanding medical information, this platform assumes no related responsibility. The platform does not endorse the descriptions and opinions expressed in the published content. If there are copyright issues, we kindly request the rights holder to contact us, and we will address the matter as soon as possible.

Click "Read More" to view more content.